Aemetis (NASDAQ:AMTX) Given New $22.00 Price Target at Ascendiant Capital Markets
by Teresa Graham · The Cerbat GemAemetis (NASDAQ:AMTX – Get Free Report) had its price objective increased by stock analysts at Ascendiant Capital Markets from $21.00 to $22.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the specialty chemicals company’s stock.
Several other research analysts have also commented on AMTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aemetis in a report on Monday, April 20th. Loop Capital set a $1.75 target price on shares of Aemetis in a research note on Thursday, March 12th. Finally, Wall Street Zen raised shares of Aemetis from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.92.
Read Our Latest Research Report on AMTX
Aemetis Stock Performance
NASDAQ AMTX opened at $2.25 on Friday. Aemetis has a one year low of $1.30 and a one year high of $3.80. The company has a 50-day simple moving average of $2.66 and a 200-day simple moving average of $1.96. The firm has a market capitalization of $158.33 million, a PE ratio of -1.89 and a beta of 1.46.
Aemetis (NASDAQ:AMTX – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The specialty chemicals company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.06). The firm had revenue of $54.62 million for the quarter, compared to analyst estimates of $66.70 million. Equities analysts forecast that Aemetis will post -1.03 earnings per share for the current year.
Institutional Trading of Aemetis
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Aemetis by 15.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,479,163 shares of the specialty chemicals company’s stock worth $5,578,000 after buying an additional 329,760 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Aemetis by 5.0% during the 4th quarter. Geode Capital Management LLC now owns 693,453 shares of the specialty chemicals company’s stock worth $964,000 after buying an additional 33,286 shares in the last quarter. Marshall Wace LLP raised its position in shares of Aemetis by 289.3% during the 4th quarter. Marshall Wace LLP now owns 559,754 shares of the specialty chemicals company’s stock worth $778,000 after buying an additional 415,978 shares in the last quarter. State Street Corp raised its holdings in shares of Aemetis by 13.9% in the 4th quarter. State Street Corp now owns 260,299 shares of the specialty chemicals company’s stock worth $362,000 after purchasing an additional 31,700 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Aemetis in the 2nd quarter worth approximately $634,000. 27.02% of the stock is currently owned by institutional investors.
About Aemetis
Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.
Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.